4Filing Date: Mar 10, 2026

Dexcom (DXCM)

Statement of Changes in Beneficial Ownership

View SEC Filing
ACC: 0001093557-26-000048
Total Value$1.59M
Trades2
Insiders1

Transaction Details

Brown Michael Jon
EVP, Chief Legal Officer·Direct
Grant · Acquire
Common Stock
Shares+39.02K
Price$0.00
Total Value$0
Shares Owned After137.93K
Transaction DateMar 8, 2026
Footnotes ▸

Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.

Brown Michael Jon
EVP, Chief Legal Officer·Direct
Tax W/H · Dispose
Common Stock
Shares-23.32K
Price$68.10
Total Value$1.59M
Shares Owned After114.60K
Transaction DateMar 8, 2026
Footnotes ▸

Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. | Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 255 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.

Post-Transaction Holdings

Brown Michael Jon · EVP, Chief Legal Officer
SecuritySharesChange
Common Stock137.93K+15.69K (12.84%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-03-08 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: DEXCOM INC (DXCM) CIK: 0001093557 --- Reporting Owner --- Name: Brown Michael Jon CIK: 0001899922 Role: Officer (EVP, Chief Legal Officer) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-03-08 | Code: A (Grant or award) Shares: +39,019 | Price: $0.00 Shares Owned After: 137,929 | Ownership: D (Direct) Footnotes: [F1] Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. [Transaction #2] Security: Common Stock Date: 2026-03-08 | Code: F (Payment of exercise/tax) Shares: -23,325 | Price: $68.10 Total Value: $1,588,432.50 Shares Owned After: 114,604 | Ownership: D (Direct) Footnotes: [F2] Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. [F3] Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 255 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. --- Footnotes (Complete Index) --- F1: Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. F3: Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 255 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. --- Signature --- /s/ /s/ Jereme M. Sylvain, as Attorney-in-Fact for Michael Jon Brown (2026-03-10)

keid analysis is for reference only and does not constitute investment advice.